Protagonist Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 543.43, 146.68, 275.93, 420.44, 623.13 ], "ebit_estimate": [ 264.1, -126.19, 29.33, 166.15, 364.11 ], "ebitda_estimate": [ 288.52, -104.72, 83.85, null, null ], "net_income_estimate": [ 275.02, -94.48, 53.07, 175.81, 345 ], "per_share_eps_estimate": [ 2.95, -1.07, 1.17, 2.52, 4.93 ], "eps_nri_estimate": [ 4.45, -0.96, 1.37, 2.61, 5.03 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ 322.7, -102.71, 114.69, 192.75, 390.23 ], "operating_cash_flow_per_share_estimate": [ 4.26, -1.2, null, null, null ], "roa_estimate": [ 28.1, -13.5, null, null, null ], "roe_estimate": [ 30.23, -11.42, 11.58, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ 300.3, -84.59, null, null, null ], "pettm_estimate": [ 44.59, 0, 112.04, 52.07, 26.66 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 213.59, 219.3, 55.99, 28.27, 29.87, 34.53, 61.3 ], "ebit_estimate": [ 126.78, 124.97, 5.61, -12.09, -11, -10, -13 ], "ebitda_estimate": [ 169.61, 198.07, -29.35, -12.85, null, null, null ], "net_income_estimate": [ 116.39, 143.43, 13.98, -3.8, -3.8, -2.8, -5.8 ], "per_share_eps_estimate": [ 1.49, 1.56, -0.12, -0.27, -0.2, -0.14, 0.22 ], "eps_nri_estimate": [ 1.94, 1.86, 0.15, -0.23, -0.2, -0.14, 0.22 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 135.38, 134.3, 45.76, -3.8, -3.8, -2.8, -5.8 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 49.22, 134.51, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }